Manufacturing complexities, low yield and stability issues have hampered the clinical translation and scaling-up of immunoliposomes to meet the needs of pharmaceutical-grade products. The authors propose a one-step method of incorporating chimeric nanobodies tagged to hydrophobic linkers into liposomes, allowing targeted delivery of small-molecule anti-cancer drugs to tumours.
- Md. Mofizur Rahman
- Jing Wang
- Yuan Wan